ResearchAndMarkets.com has added "Collaboration Deals in Pharmaceuticals 2020-2026" to its offering. The report analyzes partnership agreements announced since 2020 across the global pharmaceutical and biotechnology industry, covering collaboration structures, partnering models, transaction values, financial terms, responsibilities and leading dealmakers. It is designed for business development, licensing, legal, investment and corporate strategy professionals conducting partner evaluation, benchmarking, competitive intelligence, due diligence and negotiations. The publication includes transaction records, links to online deal records and, where available, original contracts filed with the U.S. Securities and Exchange Commission. Its coverage includes disclosed upfront payments, development and commercial milestones, royalties, rights and options, territorial and exclusivity provisions, intellectual property, research and development, clinical, regulatory, manufacturing and commercialization obligations, governance, term, renewal and termination provisions. The report examines collaboration trends by year, development phase, industry sector, therapy area, technology type and company; ranks leading deals by disclosed value; profiles the 25 most active dealmakers; and provides directories organized by company, therapy area and technology type. The research says access to source agreements can help users assess contractual provisions affecting the long-term value, governance and operational effectiveness of pharmaceutical and biotechnology alliances.